Stock 000963 HUADONG MEDICINE CO., LTD
Add to a list
To use this feature you must be a member
Log inSign up

Highlights Huadong Medicine Co., Ltd

Equities

000963

CNE0000011S1

End-of-day quote Shenzhen S.E.
Other stock markets
 23:00:00 09/05/2024 BST 		5-day change 1st Jan Change
33.41 CNY -1.04% Intraday chart for Huadong Medicine Co., Ltd +1.43% -19.42%
04-25 Huadong Medicine Co., Ltd Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
04-18 Huadong Medicine's 2023 Profit Jumps 14% MT

Highlights

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Huadong Medicine Co., Ltd Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
Huadong Medicine's 2023 Profit Jumps 14%
MT
Huadong Medicine Co., Ltd Reports Earnings Results for the Full Year Ended December 31, 2023
CI
China's first biosimilar Ozempic drug applies for approval
RE
Huadong Medicine to Build 2 Billion Yuan Biopharma Innovation Center
MT
Huadong Medicine to Invest 2 Billion Yuan in Biopharma Innovation Center
MT
Huadong Medicine's 2023 Profit to Climb Up to 14.5%
MT
Huadong Medicine's Unit Gains Chinese Drug Regulator's Nod to Trial Sirolimus Oral Solution
MT
Huadong Medicine's Unit, Partners to Invest in Pharmaceutical Firm
CI
Huadong Medicine Co., Ltd Reports Earnings Results for the Nine Months Ended September 30, 2023
CI
Huadong Medicine's Unit Gets Nod to Test Weight Management Drug; Shares Up 3%
MT
Huadong Medicine’s H1 Profit Rises 7%; EPS, Revenue Miss Forecasts
MT
Huadong Medicine Co., Ltd Reports Earnings Results for the Half Year Ended June 30, 2023
CI
Arcutis Authorizes Huadong Medicine Unit to Manufacture, Commercialize Topical Roflumilast in China, Southeast Asia
MT
Huadong Medicine Unit Gets Nod to Conduct Trial on Tumor Drug
MT
Huadong Medicine Co., Ltd Implements Final Profit Distribution Plan of A Shares for 2022, Payable on 14 June 2023
CI
Huadong Medicine Gets US FDA's Nod for Trial of Diabetes Drug
MT
Huadong Medicine Co., Ltd Approves Cash Dividend for 2022
CI
Huadong Medicine’s Q1 Profit Rises 7% as Revenue Jumps 13%
MT
Huadong Medicine Co., Ltd Reports Earnings Results for the First Quarter Ended March 31, 2023
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. 000963 Stock
  4. News Huadong Medicine Co., Ltd
  5. Highlights